Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TransMedics (TMDX) EBIT Margin (2018 - 2025)

Historic EBIT Margin for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to 16.2%.

  • TransMedics' EBIT Margin rose 125900.0% to 16.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.94%, marking a year-over-year increase of 91000.0%. This contributed to the annual value of 8.49% for FY2024, which is 203800.0% up from last year.
  • As of Q3 2025, TransMedics' EBIT Margin stood at 16.2%, which was up 125900.0% from 23.24% recorded in Q2 2025.
  • In the past 5 years, TransMedics' EBIT Margin registered a high of 23.24% during Q2 2025, and its lowest value of 216.61% during Q3 2021.
  • Its 5-year average for EBIT Margin is 34.27%, with a median of 5.03% in 2023.
  • In the last 5 years, TransMedics' EBIT Margin plummeted by -1587900bps in 2021 and then surged by 1950200bps in 2022.
  • TransMedics' EBIT Margin (Quarter) stood at 132.57% in 2021, then skyrocketed by 84bps to 21.61% in 2022, then soared by 115bps to 3.21% in 2023, then skyrocketed by 122bps to 7.11% in 2024, then surged by 128bps to 16.2% in 2025.
  • Its last three reported values are 16.2% in Q3 2025, 23.24% for Q2 2025, and 19.12% during Q1 2025.